SunRock Biopharma

SunRock Biopharma develops therapeutic antibodies against cancer. Currently SunRock’s efforts are concentrated into two pipelines:

  • The development of therapeutic antibodies against CCR9, a novel therapeutic target expressed in T-cell Acute Lymphoblastic Leukaemia.

  • The development of therapeutic antibodies against HER3, a crucial regulatory hub in many kinds of cancer, triple-negative breast cancer and colorectal cancer amongst them. This pipeline includes bispecific anti-HER3/anti-EGFR antibodies in several different formats.

UE LOGO   Logo-Xunta-Galicia   logo-vector-gain


SunRock Biopharma S.L.

Edificio CIMUS. Avenida Barcelona, s/n

15782 Santiago de Compostela. A Coruña. (España)

Tlfno.: +34 881 975 523

info@sunrockbiopharma.com